Questions, answered at the strength of the evidence

What is ipamorelin?

Ipamorelin — also written as ipamorelin peptide, ipamorelin acetate, or by its development code NNC 26-0161 — is a synthetic pentapeptide, five amino acids long, with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It is a selective agonist of GHS-R1a, the ghrelin or growth-hormone-secretagogue receptor, on pituitary cells, and it triggers a burst of growth-hormone release. It was derived from the earlier compound GHRP-1 and first characterised as "the first selective growth hormone secretagogue" because, unlike its predecessors, it did not raise ACTH or cortisol above the level seen with GHRH even at doses more than 200-fold above its growth-hormone ED50 ^[6]. It has never been approved as a drug anywhere and is sold only as a research chemical. Full detail on the ipamorelin page.

What does ipamorelin do for you?

The accurate answer is that nobody has established what it does for a healthy person, because that study has not been done. What has been measured: in healthy male volunteers it produced a single discrete pulse of growth hormone peaking about 40 minutes after dosing, with a terminal half-life of roughly two hours ^[4]. In rats, 15 days of subcutaneous dosing increased longitudinal bone growth rate in a dose-dependent way without changing total IGF-1 or bone turnover markers ^[5]. In its founding characterisation it released growth hormone potently in rat pituitary cells, rats and swine ^[6]. The one controlled human efficacy trial — in adults recovering from bowel resection — did not meet its primary endpoint ^[3]. Community reports of improved sleep and recovery exist and are anecdotal, not clinical evidence.

What are the risks of ipamorelin?

The documented risks divide into three groups. First, an evidence gap: the entire controlled human record is one seven-day intravenous Phase 2 trial ^[3] and one acute single-dose pharmacokinetic study ^[4], so there is no long-term human safety database at all. Second, class-level signals: a 28-day study of a structurally distinct GHS-R1a agonist found dose-dependent myocardial degeneration and necrosis in rats ^[2], and ipamorelin has no equivalent long-duration cardiovascular study in any species. Third, mechanistic concerns that follow from raising growth hormone — theoretical proliferative risk through IGF-1, unpredictable effects on glucose handling in anyone with existing insulin dysregulation, and a class-level appetite and adiposity effect that comes with ghrelin-receptor agonism. Add to those the practical risk of unregulated supply: research-grade material has no pharmaceutical quality assurance, so identity, purity and sterility are unverified.

What is CJC-1295?

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone, built on hGRF(1–29) with four amino-acid substitutions that block enzymatic breakdown. The variant known as CJC-1295 with DAC adds a linker that bonds covalently to Cys34 of serum albumin, which extends its half-life toward albumin's own — an estimated 5.8–8.1 days in humans ^[11]. The no-DAC form, usually sold as Modified GRF 1-29, keeps the substitutions but not the albumin hook and is short-acting. Those two forms are routinely treated as the same product and are not; the difference between them is days versus minutes ^[19]. CJC-1295 is not approved for human use anywhere, and was reviewed and not recommended for the 503A compounding bulks list in 2024. See the CJC-1295 page.

What does CJC-1295 do?

It binds the GHRH receptor on pituitary somatotrophs and activates Gs/cAMP/PKA signalling, stimulating growth-hormone synthesis and release, with IGF-1 rising downstream. In healthy adults, single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean plasma growth hormone lasting six days or more and 1.5- to 3-fold increases in IGF-1 lasting 9–11 days; after repeated doses IGF-1 stayed above baseline up to 28 days ^[11]. The finding that makes it interesting for anyone thinking about pulsatility is separate: in healthy men aged 20–40, a single dose raised basal growth hormone about 7.5-fold, mean growth hormone by about 46% and IGF-1 by about 45% a week later, while the frequency and magnitude of the pulses themselves were unaltered ^[12]. It raises the floor without erasing the beat.

Is CJC-1295 safe?

That question cannot be answered from the published record, and any source answering it confidently is going beyond its evidence. What exists is a small number of early human pharmacology studies ^[11][12][10] — no large trial, no long-term trial, no safety database in healthy adults. Known and reasoned concerns include sustained IGF-1 elevation with the DAC form and the theoretical proliferative risk that carries, growth-hormone-driven fluid retention with the nerve-compression symptoms that follow from it, reduced insulin sensitivity and higher blood glucose, and immunogenicity, which FDA briefing materials cited among the reasons for not recommending CJC-1295 for the 503A compounding bulks list in 2024 ^[8]. The original long-acting development programme was discontinued, and a patient death from that era is frequently cited alongside it; the public record does not establish causation, and the honest summary is that the question was never closed.

How much CJC-1295 should I take?

This site does not publish dosing, and the reason is not caution for its own sake — it is that no established human dosing protocol exists. CJC-1295 is not approved for human use by any regulator, so there is no label, no approved indication and no dose that has been validated against an outcome. The doses that appear in the literature belong to specific research settings: single subcutaneous doses of 30 or 60 micrograms per kilogram in the pharmacokinetic study ^[11], and 60 or 90 micrograms per kilogram in the pulsatility study ^[12]. Those are descriptions of what investigators administered under supervision in a trial, not recommendations, and neither study was designed to identify a safe or effective dose for anyone outside it. Protocols circulating online are not derived from controlled human trials. Any decision about a prescription-requiring compound belongs with a licensed clinician.

The same answer covers the combination. There is no published milligram figure for CJC-1295 and ipamorelin taken together, because the fixed blend has never been through a controlled human trial — the ipamorelin doses that do appear in the literature come from a Phase 2 trial that used 0.03 mg/kg intravenously twice daily in a hospital setting ^[3] and from an acute intravenous infusion study ^[4], neither of which studied the pairing or the subcutaneous route that community protocols use.

What is sermorelin?

Sermorelin, or sermorelin acetate, is the amidated 1–29 fragment of human growth-hormone-releasing hormone — the shortest piece of the natural 44-residue molecule that retains full activity at the GHRH receptor. It is also written GHRH(1–29), GRF(1–29) or GRF(1–29)NH2. Unlike CJC-1295, which is this same fragment with four stabilising substitutions and an albumin hook, sermorelin is unmodified and short-lived. It is the only compound on this site with a genuine regulatory history: it was FDA-approved as a branded sermorelin acetate product for pediatric growth-hormone deficiency and withdrawn from the US market in 2008 for commercial reasons, not for safety or efficacy failure. It is not a marketed FDA-approved drug today; it is available through compounding pharmacies as a Category 1 bulk drug substance under the FDA's interim Section 503A policy. Full detail on the sermorelin page.

What does sermorelin do to the body?

It binds GHRH receptors on anterior-pituitary somatotrophs and activates the adenylate cyclase / cAMP / PKA pathway, stimulating the gland to synthesise and release its own growth hormone in pulses ^[8]. Because it acts upstream on the pituitary rather than supplying growth hormone from outside, the regulatory apparatus stays connected: somatostatin can still inhibit, and IGF-1 feedback still registers — which is the basis for the editorial argument that a secretagogue is a more physiologic intervention than recombinant growth hormone ^[15]. Downstream effects are the ordinary growth-hormone ones: hepatic IGF-1 production, effects on body composition, and the known counter-regulatory effect on insulin sensitivity. In growth-hormone-deficient children, the measured effect was accelerated linear growth without excessive IGF-1 generation ^[16].

Does sermorelin work?

It depends entirely on what "work" means, and this is where most confusion about sermorelin lives. For accelerating growth in prepubertal growth-hormone-deficient children, yes — a multicentre trial recorded first-year height velocity rising from about 4.1 cm/year to roughly 7–8 cm/year on once-daily subcutaneous dosing ^[16]. For raising growth hormone and IGF-1 in adults, the mechanism is sound and the GHRH-analogue class demonstrably does this ^[8]. For the use it is actually marketed for — anti-aging, fat loss and vitality in healthy adults — the controlled evidence does not exist, and an Annals of Internal Medicine editorial concluded that growth-hormone-secretagogue use to prevent or treat the effects of aging is not yet justified by evidence ^[14]. One frequently cited cognition trial in older adults was conducted with tesamorelin, a different GHRH analogue, not with sermorelin ^[13]; presenting it as sermorelin evidence is a misreading of the source.

How long does it take for sermorelin to work?

The controlled answer and the community answer measure different things. In the pediatric trial, the endpoint was first-year height velocity — a twelve-month measurement ^[16]. In the GHRH-analogue cognition trial, the intervention ran 20 weeks before its effects on cognition, IGF-1 and body fat were assessed ^[13]. Those are the timescales on which the published research operates. Community accounts describe sermorelin as a slow burn where the first month often feels like nothing is happening and sleep or energy changes, if noticed at all, appear in the second or third month; that description is anecdotal, not clinical evidence, and it is unverified as to what was taken or from where. The mechanistic reason the timescale is long is that sermorelin does not supply a hormone directly — it asks a gland to do something, and the downstream effects accumulate through IGF-1 over weeks.

What is CJC-1295 / Ipamorelin good for?

In the published literature, nothing — because the fixed combination has never been evaluated in a controlled human trial for any outcome. What can be said is what its components and its class have been studied for. The GHRH-analogue arm has strong evidence in the form of a meta-analysis of five randomised controlled trials of tesamorelin, which found reductions in visceral adipose tissue (−27.71 cm²) and hepatic fat (−4.28%), an increase in lean body mass of 1.42 kg and raised IGF-1, with no serious adverse events ^[17] — evidence about tesamorelin, in a defined patient population. A class review of growth-hormone secretagogues found them well tolerated overall, with raised blood glucose from decreased insulin sensitivity as the chief concern and long-term cancer and mortality data still needed ^[18]. The combination-specific result in the corpus is preclinical: improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model, reported in a review that explicitly declines to make clinical recommendations ^[7].

What are the bad side effects of CJC-1295 and Ipamorelin?

No controlled trial of the combination has catalogued its adverse effects, so what follows is class-level reasoning plus community report. Mechanistically expected: fluid retention and puffiness, carpal-tunnel-type tingling from that fluid pressing on the wrist nerve, joint pain, and reduced insulin sensitivity with raised blood glucose — the last of which a class review identifies as the chief safety concern for growth-hormone secretagogues ^[18]. Because the CJC-1295 half raises growth hormone and IGF-1 for days after a single dose ^[11], those effects are sustained rather than transient. Community reports, which are anecdotal, not clinical evidence, most often mention injection-site redness or itching, water retention in the first month, a brief facial flush or head-rush minutes after dosing, grogginess, lightheadedness and increased appetite attributed to the ghrelin arm. The unresolved concerns are the serious ones: no long-term human safety data, no carcinogenicity study of the blend, and unverified purity in unregulated supply.

How long do CJC-1295 and Ipamorelin take to work?

"Work" needs splitting into two questions, because the two halves operate on timescales two orders of magnitude apart. Pharmacologically, ipamorelin acts almost immediately: its growth-hormone response peaks about 40 minutes after dosing and the peptide is largely cleared within a couple of hours ^[4]. CJC-1295 with DAC works over days — a single subcutaneous dose held mean plasma growth hormone 2- to 10-fold above baseline for six days or more and IGF-1 elevated for 9–11 days, with IGF-1 staying above baseline up to 28 days after repeated dosing ^[11]. So hormone changes begin within an hour and accumulate over weeks. Whether any of that translates into an effect a person would notice is a different question, and it is unanswered: no controlled human trial of the combination has measured a clinical outcome on any timescale. Community accounts describing changes at one to two weeks for sleep and around week five for body composition are anecdotal, not clinical evidence.